UnknownNot Applicable

Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease

20 participantsStarted 2023-02-28

Plain-language summary

This study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ≥18 years, male and female. * With IGG4-related disease. Exclusion Criteria: * Inoculate live vaccine within 4 weeks before screening. * Treponema pallidum antibody positive in screening period. * Active hepatitis in screening period. * With a history of solid organ or cell transplantation within 6 months before screening. * With other medical or non-medical conditions that are not suitable for the study by the investigator.

What they're measuring

Response rate

Timeframe: up to week 12

Trial details

NCT IDNCT05728684

SponsorBeijing Friendship Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-02-28

View on ClinicalTrials.gov More IgG4 Related Disease trials